Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-grade Serous Ovarian Carcinoma
Conditions
High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
Trial Timeline
Jul 25, 2022 → Oct 16, 2024
NCT ID
NCT05446870About Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel is a phase 2 stage product being developed by Merck for High-grade Serous Ovarian Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05446870. Target conditions include High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05446870 | Phase 2 | Completed |
Competing Products
8 competing products in High-grade Serous Ovarian Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| BMS-986463 | Bristol Myers Squibb | Phase 1 | 32 |
| Mebendazole | Brain Biotech | Phase 1 | 25 |
| Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells | Brain Biotech | Phase 1 | 25 |
| APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 1/2 | 33 |
| APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 2 | 44 |